The private equity bet that coronavirus cut short

The private equity bet that coronavirus cut short

Last December executives at the Carlyle Group worked into the night to sign what they imagined would be one of the private equity firm’s most enduring deals. In 2020, however, there may be no such thing as a stable business. Carlyle is now trying to walk away from a deal with American Express Global Business Travel before any money has changed hands. Our US private capital correspondent, Mark Vandevelde, reports on the ensuing legal row, and what it could mean for dealmaking during the pandemic.


To get free access to the FT’s Coronavirus Business Update newsletter for 30 days, visit ft.com/behindthemoneycovid or https://www.ft.com/newsletter-signup/coronavirus?segmentId=12f1abd6-6f16-e2df-e4ff-7aaa9346f98e.


A few stories for further reading:

Hosted on Acast. See acast.com/privacy for more information.

Episoder(321)

Coming soon: The cost of corporate whistleblowing in the UK

Coming soon: The cost of corporate whistleblowing in the UK

For years, corporate whistleblowers in the UK have found themselves in an unenviable predicament. They’re encouraged to report wrongdoing, but at the same time they often feel like they’ve risked thei...

5 Des 20251min

Business History: The Secret of Southwest’s Success

Business History: The Secret of Southwest’s Success

This week we’re sharing an episode from Business History, a podcast from Pushkin Industries. Former Planet Money hosts Jacob Goldstein and Robert Smith explore what the businesses of the past can teac...

3 Des 202552min

KKR, Bain and private equity’s push into Japan

KKR, Bain and private equity’s push into Japan

When international private equity groups first entered Japan at the turn of the 21st century, newspapers criticised them as vulture funds and politicians steered clear of public contact. Today, it’s a...

26 Nov 202521min

Coming soon from Tech Tonic: Defying death

Coming soon from Tech Tonic: Defying death

Investors are spending billions of dollars on novel ways to extend human life through inventive treatments, therapies, and even manipulating our genes. And increasingly, it seems as though anti-ageing...

24 Nov 20251min

What’s the deal with OpenAI's deals?

What’s the deal with OpenAI's deals?

OpenAI is entering a new era. It's restructured to add a for-profit arm to its business and has signed more than a trillion dollars’ worth of deals to secure chips and build out data centres. But thos...

19 Nov 202526min

Pfizer and Novo Nordisk’s $10bn battle over weight-loss drugs

Pfizer and Novo Nordisk’s $10bn battle over weight-loss drugs

Pharma juggernauts Pfizer and Novo Nordisk are struggling in the obesity drug race.The two companies are searching for their next moneymaker, and that search recently spun out into a ferocious, multib...

12 Nov 202526min

The $17bn nuclear start-up without any revenue

The $17bn nuclear start-up without any revenue

Publicly-listed Oklo sits at the intersection of two hot areas for Wall Street: artificial intelligence and energy companies. This year alone, Oklo’s share price has jumped more than 400 per cent. But...

5 Nov 202523min

$12bn of debt: How First Brands Group collapsed

$12bn of debt: How First Brands Group collapsed

Some of the world’s biggest financial institutions are reeling after the collapse of a little-known car parts supplier: First Brands Group. The company filed for bankruptcy last month, and since then,...

29 Okt 202526min

Populært innen Business og økonomi

stopp-verden
lydartikler-fra-aftenposten
dine-penger-pengeradet
e24-podden
rss-penger-polser-og-politikk
rss-borsmorgen-okonominyhetene
pengepodden-2
pengesnakk
livet-pa-veien-med-jan-erik-larssen
rss-politisk-preik
utbytte
morgenkaffen-med-finansavisen
tid-er-penger-en-podcast-med-peter-warren
finansredaksjonen
lederpodden
stormkast-med-valebrokk-stordalen
rss-markedspuls-2
liberal-halvtime
rss-sunn-okonomi
rss-pa-konto